-
Mashup Score: 0
– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) – – PDUFA target action date of December 8, 2023 , for SCD and March 30, 2024 , for TDT –
Source: CRISPR TherapeuticsCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Sinusoidal obstruction syndrome, also known as veno-occlusive disease, is a potentially life-threatening complication of haematopoietic stem-cell tran…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Just out in @TheLancetHaem Defibritode RCT for #VOD prevention in #HSCT - no difference in VOD-free survival between DF and best supportive care - no safety signal in this RCT - bleeding similar between arms https://t.co/2lcND2uywG
-
-
Mashup Score: 2Is $3.5 Million a Fair Price for a Lifesaving Gene Therapy? - 2 year(s) ago
Here’s why gene therapies are the most expensive drugs in the world —and how these groundbreaking treatments could severely strain our health care system.
Source: WebMDCategories: Hem/Oncs, Latest HeadlinesTweet-
Price and value and access all coming together. Is $3.5 Million a Fair Price for a Lifesaving Gene Therapy? https://t.co/UZ4Fb1Lwq6 from @WebMD;
-
-
Mashup Score: 56Advancing CAR T cell therapy through the use of multidimensional omics data - Nature Reviews Clinical Oncology - 2 year(s) ago
Data obtained using omics technologies can offer important insights into various aspects of chimeric antigen receptor (CAR) T cell therapy. In this Review, the authors provide an overview of the multidimensional profiling technologies that have been applied in investigations of CAR T cell therapy. They then discuss the ways in which multi-omics data obtained through such analyses can be used to…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @GreenLymphoLab: Advancing CAR T cell therapy through the use of multidimensional omics data. https://t.co/cJcIw4zWLI
-
-
Mashup Score: 0
Across social media, headlines this week said that single use coffee pods may be more climate friendly than other ways of making coffee. That may not be the case, based on the science.
Source: NPRCategories: Hem/Oncs, Latest HeadlinesTweet-
Exactly my thought when I read those articles about thousands of dumpster loads of @Keurig pods being the "environmentally friendly" choice. Plastic coffee pods may not a great enviro choice https://t.co/zJlYRUAeym PS how does @TerraCycle really recycle the pods we send them?
-
-
Mashup Score: 2365Outdated Periodic Table - 2 year(s) ago
Comics I enjoy: Three Word Phrase, SMBC, Dinosaur Comics, Oglaf (nsfw), A Softer World, Buttersafe, Perry Bible Fellowship, Questionable Content, Buttercup Festival, Homestuck, Junior Scientist Power Hour xkcd.com is best viewed with Netscape Navigator 4.0 or below on a Pentium 3±1 emulated in Javascript on an…
Source: xkcdCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @xkcd: Outdated Periodic Table https://t.co/MvlGGo3dG0 https://t.co/LD1Dco4bXl
-
-
Mashup Score: 2Highly Cited Researchers - Clarivate - 2 year(s) ago
Highly Cited Researchers have demonstrated significant and broad influence reflected in their publication of multiple highly cited papers over the last decade.
Source: ClarivateCategories: Hem/Oncs, Latest HeadlinesTweet-
Honored to be on this list on behalf of the amazing group of clinical and basic researchers it is my privilege to work with. https://t.co/bdLblEdPqp
-
-
Mashup Score: 5
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
ELIANA Three-Year Update of Tisa-cel (#Kymriah) is out in @JCO_ASCO @NovartisCancer @CHOP_Research @CHOPCancerCntr https://t.co/PTPnfiSKKo https://t.co/6tMJ63Kvsw
-
-
Mashup Score: 0How an experimental treatment beat a little girl's cancer - 3 year(s) ago
When Emily Whitehead was six years old, she became the first child ever to receive genetically-modified T cells, an experimental treatment for her leukemia. It cured her, and helped launch the field of cellular medicine.
Source: www.cbsnews.comCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest on CBS @CHOPCancerCntr https://t.co/bp5F9zKUjt
-
-
Mashup Score: 0‘A Crisis Coming’: The Twin Threats to American Democracy - 3 year(s) ago
The United States faces two distinct challenges, the movement by Republicans who refuse to accept defeat in an election and a growing disconnect between political power and public opinion.
Source: www.nytimes.comCategories: Hem/Oncs, Latest HeadlinesTweet-
via @nytimes Comprehensive and fact based article about where we are. Every civics class and every political debate I have ever witnessed called our country a democracy. And now we’re hearing it isn’t. https://t.co/SKtUXyMPJv
-
Very excited to see info on the FDA acceptance of BLAs for #sicklecell disease and thalassemia with @VertexPharma exa-cel product. First CRISPR-engineered cell therapy product, hopefully the first of many. Looking forward to updated data at #EHA2023 https://t.co/czUijbe2rM